US · 2 sources covering this

GSK to buy US cancer treatment firm Nuvalent for $10.6bn

British drugmaker’s new chief executive Luke Miels announces one of its biggest deals Business live – latest updates GSK’s new boss Luke Miels has struck one of the British drugmaker’s biggest deals, announcing the $10.6bn (£7.9bn) acquisition of a US cancer specialist with two-late stage medications. The FTSE 100 company is boosting its oncology portfolio by agreeing to buy Nuvalent, a Boston-based company that develops cancer drugs, including three for lung cancer. Continue reading...

Share:X WhatsApp Reddit Facebook LinkedIn Open ↗

Coverage spectrum

2 L · 0 C · 0 R

How 2 sources are covering this

The GuardianLean L·1h ago
GSK to buy US cancer treatment firm Nuvalent for $10.6bn
British drugmaker’s new chief executive Luke Miels announces one of its biggest deals Business live – latest updates GSK’s new boss Luke Miels has struck one of the British drugmaker’s biggest deals, announcing the $10.6bn (£7.9bn) acquisition of a US cancer specialist with two-late stage medications. The FTSE 100 company is boosting its oncology portfolio by agreeing to buy Nuvalent, a Boston-based company that develops cancer drugs, including three for lung cancer. Continue reading...
Read at The Guardian →
The GuardianLean L

Embed this bias spectrum on your site

Paste this iframe wherever you'd like the widget to appear. Resizes responsively; no JS required.

<iframe
  src="https://statesidedaily.com/embed/cluster/66167df27d555533db40c5cb78b851039befc3db"
  width="100%" height="320"
  style="border:0;max-width:680px"
  loading="lazy"
  title="GSK to buy US cancer treatment firm Nuvalent for $10.6bn"></iframe>

GSK to buy US cancer treatment firm Nuvalent for $10.6bn

How 2 sources are covering this